Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of LBL-024 in advanced malignant tumors
CTR20213023Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in Non-hematologic malignancy, neuroendocrine carcinoma (NEC), sponsored by Leads Biolabs. Started Jan 2022; status: active.
02
Drugs
opamtistomig
03
Conditions
Non-hematologic malignancyneuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20213023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213023.